A joint comment outlines a series of immediate actions the FDA can take to speed up ALS therapy development

Posted on Monday, March 25, 2013 - 12:12, By: ALSN Staff
The Muscular Dystrophy Association and The ALS Association (ALSA) submitted a joint comment to the U.S. Food and Drug Administration (FDA) today, commending and thanking the agency for convening its first-ever ALS public hearing on Feb.

Research news about clinical trials testing a Parkinson’s drug and stem cells in ALS reported at the 65th annual meeting of the American Academy of Neurology

Posted on Friday, March 22, 2013 - 16:45, By: Amy Madsen
Update (July 30, 2013): BrainStorm Cell Therapeutics announced in a July 29, 2013, press release that the European Commission has granted Orphan Drug Designation to the company’s NurOwn stem cell therapy for the treatment of ALS.

A phase 2 clinical trial of the diabetes drug pioglitazone in ALS was terminated after it failed to reach its primary endpoint of increased survival time

Posted on Tuesday, June 19, 2012 - 03:05, By: Other
The anti-diabetic drug pioglitazone did not improve survival time when tested as an add-on therapy to riluzole in a phase 2 clinical trial of people with amyotrophic lateral sclerosis (ALS). The trial, which was conducted in Germany, was stopped early "for futility" when interim results showed no...